Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 3/20 | 0.40 |
| ▸ | MME | P08473 | 2/20 | 0.33 |
| ▸ | CTSK | P43235 | 4/20 | 0.32 |
| ▸ | CTSS | P25774 | 3/20 | 0.32 |
| ▸ | PRKCA | P17252 | 1/20 | 0.32 |
| ▸ | CTSL | P07711 | 1/20 | 0.30 |
| ▸ | CTSB | P07858 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19318522 | 1.00 | TGFBR1 (0.40) | TGFBR1MMECTSKCTSSPRKCA | |
| SCHEMBL13223900 | 1.00 | TGFBR1 (0.40) | TGFBR1MMECTSKCTSSPRKCA | |
| SCHEMBL8906540 | 0.84 | CTSK (0.41) | CTSKCTSSCTSLCTSBCA1 | |
| SCHEMBL8906526 | 0.84 | CTSK (0.41) | CTSKCTSSCTSLCTSBCA1 | |
| SCHEMBL19318525 | 0.82 | CTSS (0.34) | CTSKCTSSCTSLCTSBCA1 | |
| SCHEMBL8906249 | 0.82 | CTSS (0.34) | CTSKCTSSCTSLCTSBCA1 | |
| SCHEMBL13223906 | 0.81 | CTSL (0.44) | CTSKCTSSCTSLCTSB | |
| SCHEMBL12598695 | 0.81 | CTSK (0.44) | CTSKCTSSCTSLCA1CA2 | |
| SCHEMBL13223901 | 0.81 | CTSL (0.44) | CTSKCTSSCTSLCTSB | |
| SCHEMBL14930706 | 0.81 | CTSS (0.35) | CTSKCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100215618-A1 | NOVEL COMPOUNDS - 644 | ARROW THERAPEUTICS LIMITED (GB) | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100215618-A1 | NOVEL COMPOUNDS - 644 | NR1H4, HAVCR2, CYP3A4 | TGFBR1 567/4885MME 2049/4885CTSK 3637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.